Rosacea News May 2010

Rosacea News May 2010

1. Cetaphil RestoraDERM for extra dry skin and Eczema

Already available in Canada, Cetaphil will introduce a new line of products for dry sensitive skin in August in the US. The line is called RestoraDERM and is targeted at Eczema sufferers who struggle to maintain the natural moisture balance of their skin. For those rosacea sufferers who also …

2. Research Briefs: IPL, Laser and Stress

Here are brief mentions of recently published papers that look interesting to rosacea sufferers.

1. Intense pulsed light in the treatment of non-aesthetic facial and neck vascular lesions: report of 85 cases

IPL treatments were given 4-6 times 3 weeks apart. 35 rosacea `lesions’ were studied overall. The abstract links the results of rosacea and Poikiloderma of Civatte together, saying that the vast majority of lesions …

3. NRS on Beta Blockers and flushing

In the latest edition of Ask the Doctors, Dr. Jonathan Wilkin, chairman of the NRS medical advisory board answers the question `Do beta-blockers help reduce flushing from rosacea?’.

The answer is brief but I’m encouraged to see the NRS discussing further the possibility of using beta blockers for flushing in rosacea sufferers.
In severe cases, a beta-blocker may sometimes be prescribed to help reduce emotionally triggered flushing …

4. Atralin Gel (Tretinoin 0.05%) being trialled for the redness of Rosacea

The Clinical Trials Register is listing a new trial today for a topical retinoid, Atralin Gel 0.05% for the treatment of the redness and broken blood vessels of rosacea. Officially the trial will look at the redness, telangiectasia, …

5. SIG990 Excellent for Redness, several years away

In a recent email to Rosacea News, Dr. Eduardo Pérez, VP of Operations at Signum Biosciences has confirmed that SIG990 is undergoing preclinical safety/toxicology testing as required by the FDA before clinical trials can commence. You can see this confirmed at the company’s web site: Pharmaceutical Development Pipeline. Signum Biosciences has several molecules under development, SIG990 is their lead candidate for rosacea. …

6. Afamelanotide (Scenesse) now available in Italy

Clinuvel has announced today that Italy has pre-empted the approval of Afamelanotide by the FDA in the US by approving it for the treatment of erythropoietic protoporphyria (EPP).

7. An interview with Colin Dahl from Australian Sciences

Our first guest is Colin Dahl, Chief Scientist at Australian Sciences and the author of A Practical Understanding of Rosacea, Part 1: Heat Regulation and the Warm Room Flush Phenomenon that has been of great help to many rosacea sufferers. We hope you will find these interviews an interesting read.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s